Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis

NCT01644110 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01644110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01644110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
Lead sponsor
University of Ulm
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2013
Completion date
April 27, 2024
Enrollment
96 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pmf, post-et mf, post-pv mf, primary myelofibrosis, secondary myelofibrosis, smf